enzastaurin has been researched along with Glioma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Ma, W; Wang, J; Yan, C; Yang, Y | 1 |
| Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ | 1 |
| Butman, JA; Fine, HA; Fraum, TJ; Iwamoto, FM; Kreisl, TN; Li, A; Moustakas, A; Odia, Y; Salgado, CA; Sul, J | 1 |
| Frank, B; Lemke, D; Maurer, G; Rieger, J; Tabatabai, G; Weiler, M; Weller, M; Wick, W | 1 |
| Albert, PS; Duic, P; Fine, HA; Kim, L; Kotliarova, S; Kreisl, TN; Moore, K; Musib, L; Thornton, D; Walling, J | 1 |
| Jane, EP; Pollack, IF | 2 |
| Albert, PS; Butman, JA; Fine, HA; Kim, L; Kotliarova, S; Kreisl, TN; Musib, L; Thornton, D | 1 |
| Stummer, W | 1 |
| Christ, G; Frank, B; Heckl, S; Lemke, D; Obermüller, U; Tabatabai, G; von Kürthy, G; Weller, M; Wick, A; Wick, W | 1 |
1 review(s) available for enzastaurin and Glioma
| Article | Year |
|---|---|
Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
Topics: Angiogenesis Inhibitors; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Glioma; Humans; Indoles; Molecular Targeted Therapy; Prognosis; Snake Venoms | 2019 |
3 trial(s) available for enzastaurin and Glioma
| Article | Year |
|---|---|
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Follow-Up Studies; Glioma; Glycogen Synthase Kinase 3; Humans; Indoles; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate | 2016 |
A phase I trial of enzastaurin in patients with recurrent gliomas.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Glioma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Long QT Syndrome; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Phosphoproteins; Protein Kinase C; Protein Kinase C beta; Survival Analysis; Thrombocytopenia | 2009 |
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Indoles; Kaplan-Meier Estimate; Neoplasm Recurrence, Local | 2010 |
6 other study(ies) available for enzastaurin and Glioma
| Article | Year |
|---|---|
The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Cerebral Hemorrhage; Female; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Radiotherapy; Treatment Outcome | 2016 |
Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.
Topics: Adult; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-X Protein; Brain Neoplasms; Caspases; Cell Line, Tumor; Cytochromes c; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Mitochondria; Protein Kinase C; Proto-Oncogene Proteins c-akt; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2008 |
Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 2; Dose-Response Relationship, Drug; Glioma; Histones; Humans; Indoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; STAT1 Transcription Factor | 2010 |
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Synergistic antiglioma activity of radiotherapy and enzastaurin.
Topics: Animals; Apoptosis; Brain Neoplasms; Combined Modality Therapy; Glioma; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Survival Analysis; Up-Regulation; Vascular Endothelial Growth Factor A | 2007 |
The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.
Topics: Apoptosis; Benzoquinones; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytochromes c; Down-Regulation; Drug Synergism; Glioma; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Oncogene Protein v-akt; Phosphorylation | 2008 |